1214735-16-6

Basic information

• Product Name: BMS-790052
• Synonyms: Daclatasvir (BMS-790052)
• CAS NO: 1214735-16-6
• Molecular Formula: C40H50N8O6
• Molecular Weight: 738.875
• Mol File: 1214735-16-6.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 1071.239 °C at 760 mmHg
• Flash Point: 601.664 °C
• Appearance: /
• Density: 1.25 g/cm³
• CAS DataBase Reference: BMS-790052(CAS DataBase Reference)
• NIST Chemistry Reference: BMS-790052(1214735-16-6)
• EPA Substance Registry System: BMS-790052(1214735-16-6)

Safety Data

• Hazardous Substances Data: 1214735-16-6(Hazardous Substances Data)

Usage

General Description

BMS-790052 is a chemical compound that belongs to a class of drugs known as hepatitis C virus (HCV) NS5A inhibitors. BMS-790052 has shown potent inhibition of HCV replication in preclinical studies and has the potential to be an effective treatment for HCV infections. BMS-790052 works by targeting the NS5A protein, which is essential for the replication of the hepatitis C virus. Clinical trials have shown promising results for BMS-790052 in combination with other antiviral drugs, and it may offer a new option for patients with chronic HCV infections. However, further research is needed to fully understand the safety and efficacy of BMS-790052 as a treatment for hepatitis C.

InChI:InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1

Upstream product

• 1009119-83-8 methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate hydrochloride 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 79-22-1 methyl chloroformate 
• 1007882-27-0 2-[(2S)-pyrrolidin-2-yl]-5-[4-(4-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)phenyl]-1H-imidazole 
• 1007882-23-6 methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate 
• 1009119-83-8 1H-imidazole,5,5'-[1,1'-biphenyl]-4,4'-bis[2-(2S)-2-pyrrolidine-2yl hydrochloride] 

Downstream Products

• 1312335-96-8 C₄₀H₄₈Br₂N₈O₆ 

Relevant articles and documents

Micro-electro-flow reactor (μ-EFR) system for ultra-fast arene synthesis and manufacture of daclatasvir

The World Health Organization (WHO) has listed daclatasvir (DCV), symmetrical arene, as one of the essential medicines for human health. DCV manufacturing is usually carried out in a non-continuous or "batch" approach over multiple locations and is severely limited by long production times (3-10 days), resulting in non-affordability (highly expensive) and disruption of the potential chain supply. Here, we report the total process system including the development of a novel electro-flow reactor containing patterned electrodeposited Ni or Pt nanoparticles over a copper electrode for a C-C coupling reaction in a co-reductant/oxidant-free, ultra-fast process for symmetrical substituted/unsubstituted biphenyl synthesis. This method was further extended to a new generation commercial batch synthetic route for continuous flow ultra-fast daclatasvir synthesis in 33.2 min. We envisage that this micro-electro-flow reactor (μ-EFR) system platform will substantially enable advances in continuous-μ-flow fine chemical manufacturing, multistep reaction sequences, reaction devising equipment, and real-time extraction.

Synthetic method of daclatasvir

The invention discloses a synthetic method of daclatasvir. The method adopts bis(2-bromoacetyl) biphenyl and t-butyloxycarboryl-L-proline as initial raw materials, the initial raw materials are separately synthesized into a midbody N-4, N-3, N-2 and N-1 i

PROCESS FOR THE PREPARATION OF DACLATASVIR

The present disclosure provides a novel process for the preparation of daclatasvir or pharmaceutically acceptable salts thereof using novel intermediates. Formula (I)